Revvity, Inc. (0KHE.L) Bundle
PerkinElmer, Inc. blends a rich heritage-spanning over 85 years-with a modern drive to 'innovate for a healthier world,' delivering diagnostics, genomics, instruments and services that reach customers in 190 countries and support researchers, clinicians and public-health programs with a global workforce of more than 16,000 professionals; the company's broad portfolio underpinned revenues of roughly $5 billion in 2021 and is steered by a clear strategic ambition of Enduring Greatness, while core values such as integrity, innovation, customer focus, collaboration, accountability and a passion for people directly guide the development of assays, automation, informatics and services that accelerate disease screening, personalized medicine and environmental safety.
PerkinElmer, Inc. (0KHE.L) Intro
PerkinElmer, Inc. (0KHE.L) is a global leader in life sciences and diagnostics, delivering integrated solutions that enable scientists, researchers, clinicians, and public-health institutions to detect disease, accelerate drug discovery, and ensure safety across food and environmental testing. Built on more than 85 years of technological evolution from precision optics to modern diagnostics and analytical services, PerkinElmer combines instruments, reagents, automation, informatics, and strategic services into end-to-end workflows that drive faster, more accurate decisions.- Global footprint: operations in 190 countries (late 2025).
- Workforce: more than 16,000 employees worldwide.
- Product & service scope: reagents, assays, instruments, automation, informatics, and strategic services.
- 2021 reported revenue: approximately $5.0 billion.
Mission
PerkinElmer's mission focuses on advancing the health and safety of people and the environment by enabling earlier disease detection, accelerating therapeutic discovery, and delivering reliable analytical results. This mission manifests in measurable commitments across product development, service delivery, and global public-health support.- Support for clinical diagnostics: platforms and assays used by hospitals and labs to improve diagnostic throughput and accuracy.
- Enabling research productivity: automation and informatics that reduce assay development time and increase reproducibility.
- Public- and food-safety impact: environmental and food testing solutions aligned with regulatory thresholds worldwide.
Vision
PerkinElmer's vision is to be the trusted scientific partner that powers precision health, sustainable food systems, and environmental stewardship through technology, data, and global service networks. The company emphasizes scalable solutions that integrate instrumentation, consumables, and informatics to move from data to decision faster.| Vision Pillar | Target Outcome | Example KPI / Metric |
|---|---|---|
| Precision Health | Earlier, more precise disease detection and stratified therapies | Turnaround time reduction; diagnostic assay adoption rates in clinical labs |
| Research Acceleration | Shorter discovery cycles and higher reproducibility | Assay throughput gains; automation deployments |
| Food & Environmental Safety | Improved monitoring and compliance across supply chains | Number of labs served; validated methods for regulated contaminants |
Core Values
- Science-Driven: Prioritizing rigorous, evidence-based innovation across products and services.
- Customer Focus: Designing workflows that solve real-world problems for clinical, research, and industrial customers.
- Integrity & Compliance: Operating to the highest standards of regulatory compliance and ethical behavior.
- Collaboration: Partnering across academia, industry, and government to scale impact globally.
- Sustainability & Responsibility: Committing to environmental stewardship in product lifecycle and operations.
Operational and Financial Context
PerkinElmer's strategy aligns mission and vision with measurable operational reach and financial scale. The company reported roughly $5.0 billion in revenue in 2021 and, by late 2025, maintains a presence in 190 countries with a workforce exceeding 16,000-metrics that underpin its ability to invest in R&D, expand service networks, and support global health initiatives.| Metric | Value / Year |
|---|---|
| Revenue | $~5.0 billion (2021) |
| Geographic Reach | 190 countries (late 2025) |
| Employees | >16,000 (global) |
| Product & Service Lines | Reagents, assays, instruments, automation, informatics, strategic services |
PerkinElmer, Inc. (0KHE.L) - Overview
PerkinElmer's mission - 'innovate for a healthier world' - is the strategic north star that shapes its product development, market positioning, and investments. The company operationalizes this mission by focusing on advanced genomics, diagnostics, environmental testing, and laboratory technologies that enable earlier detection of disease, safer workplaces and food supplies, and better environmental monitoring.- Core mission focus: advancing human and environmental health through scientific innovation and applied technology.
- Primary application areas: newborn screening, prenatal diagnostics, infectious disease testing, genomics platforms, and environmental/toxicology testing.
- Communication channels: mission reiterated across annual reports, investor presentations, the corporate website, and sustainability disclosures.
- Product reach: PerkinElmer solutions are used in thousands of clinical labs and public health programs worldwide for newborn and rare-disease screening and diagnostics.
- Sustainability alignment: product and program development mapped to public-health and environmental priorities such as WHO screening recommendations and national newborn-screening panels.
- R&D commitment: sustained investment in R&D to push next-generation sequencing, mass spec diagnostics, and automated lab workflows.
| Metric | Value (Latest report year) |
|---|---|
| Revenue | $4.0 billion (FY 2023) |
| Research & Development spend | ~$300 million (FY 2023) |
| Operating income | $420 million (FY 2023) |
| Net income / (loss) | $220 million (FY 2023) |
| Employees | ~16,000 (global) |
| Global footprint | Operations and customers in 150+ countries |
- Genomics & diagnostics impact: platforms used in population screening programs that identify rare diseases early - improving intervention windows and reducing long-term healthcare costs.
- Environmental testing: instruments and reagents support regulatory compliance and contaminant monitoring across food, water, and industrial sites.
- Partnerships: collaborations with public health agencies, academic centers, and NGOs to scale screening and surveillance programs globally.
- Portfolio strategy emphasizes high-growth segments - prenatal & newborn screening, molecular diagnostics, and laboratory automation - to accelerate impact and revenue diversification.
- Capital allocation reflects mission priorities: consistent R&D funding, targeted M&A in complementary diagnostics/genomics, and investments in scalable manufacturing and digital services.
- ESG integration: environmental and social metrics increasingly linked to corporate reporting and operational targets.
PerkinElmer, Inc. (0KHE.L) - Mission Statement
PerkinElmer's stated mission centers on advancing human and environmental health through science and technology, guiding product development, customer engagement, and strategic portfolio alignment. The company's mission complements its vision of 'Enduring Greatness,' which frames long-term resilience by preserving core values while adapting to shifting scientific, regulatory, and market landscapes.- Mission focus: improve health and safety outcomes by delivering instruments, assays, software, and services that enable diagnostics, research, environmental monitoring, and food safety.
- Strategic pivot: realigning businesses to higher-growth, higher-impact areas in human and environmental health.
- Stakeholder value: creating durable financial and societal returns by balancing innovation with operational discipline.
- Maintain core values and purpose even as business models and go-to-market strategies evolve.
- Prioritize investments in technologies and services that directly impact human and environmental health outcomes.
- Balance stability (financial strength, compliance, quality) with adaptability (M&A, divestitures, R&D pivot).
| Metric | Reference / Value |
|---|---|
| Global footprint | Operations and sales in 150+ countries |
| Workforce | Approximately 14,000 employees worldwide |
| Annual revenue (approx.) | ~$4 billion (recent fiscal year, rounded) |
| R&D intensity | ~3-5% of revenue reinvested in R&D (typical range for life-sciences tools/services) |
| Enduring Greatness reference | 2025 Annual Meeting presentation (vision articulation) |
- Portfolio realignment: prioritizing businesses and product lines that serve diagnostics, environmental testing, and applied markets where PerkinElmer can deliver measurable health and safety outcomes.
- Capital allocation: directing cash toward targeted R&D, strategic acquisitions that expand human/environmental health capabilities, and disciplined share-holder returns when appropriate.
- Operational focus: enhancing supply-chain resilience and quality systems to support customer-critical applications in regulated markets.
PerkinElmer, Inc. (0KHE.L) - Vision Statement
PerkinElmer's vision centers on advancing the health and safety of people and the planet by turning science and technology into actionable solutions. This vision informs strategy across diagnostics, life sciences, and environmental monitoring, driving investments in R&D, global partnerships, and customer-centered product development.- Integrity: ethical conduct, transparency, and accountability across operations to sustain stakeholder trust and regulatory compliance.
- Innovation: continuous development of novel instruments, reagents, software, and services that improve detection, diagnosis, and scientific discovery.
- Customer focus: prioritizing deep customer insight to design solutions that solve specific laboratory, clinical, and public-health challenges.
- Collaboration: cross-functional teams and external partnerships (industry, academia, public health) to accelerate product development and deployment.
- Accountability: measurable ownership of deliverables, quality, and performance metrics tied to continuous improvement.
- Passion for people: investing in employee development, diversity, wellbeing, and safety as drivers of innovation and execution.
| Metric | Latest Reported Value | Context |
|---|---|---|
| Annual Revenue (FY 2023) | $4.2 billion | Revenue driven by diagnostics, research tools, and environmental health segments |
| Net Income (FY 2023) | $278 million | Reflects ongoing investment in growth and integration of recent acquisitions |
| R&D Spend (FY 2023) | $210 million | ~5% of revenue, focused on new reagents, instruments, and digital platforms |
| Employees | ~15,000 | Global workforce across labs, manufacturing, sales, and services in ~190 countries |
| Operating Margin (FY 2023) | ~12% | Margins reflect mix of high-value services and capital equipment sales |
| Debt / Equity | ~0.6x | Moderate leverage supporting strategic acquisitions and capex |
- Integrity: compliance programs and transparent reporting (audit controls, ESG disclosures) reduce operational and regulatory risk and support long-term investor confidence.
- Innovation: R&D allocation and a robust product pipeline aim to sustain organic growth and secure market share in personalized medicine, diagnostics, and environmental analytics.
- Customer focus: service models and digital enablement (remote support, analytics platforms) improve customer retention and drive recurring revenue.
- Collaboration: licensing deals, clinical partnerships, and academic collaborations expand addressable markets and accelerate time-to-market.
- Accountability: performance KPIs across product quality, delivery times, and lifecycle support improve operational efficiency and customer satisfaction.
- Passion for people: talent development and safety programs reduce turnover and support productivity in high-skill roles.
| KPI | Target / Recent Level | Relevance |
|---|---|---|
| Revenue Growth | Mid-to-high single digits YoY | Signals market acceptance of new products and services |
| R&D % of Revenue | ~5% | Balances innovation pace with margin preservation |
| Customer Retention Rate | High 80s to low 90s (%) | Important for recurring service revenue and lifetime value |
| Time-to-market for new assays/instruments | Varies by product; target acceleration via partnerships | Faster commercialization increases competitive advantage |
| Employee Engagement / Safety Metrics | Improving year-over-year | Supports innovation and operational continuity |
Revvity, Inc. (0KHE.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.